A connected system around an existing care task
GlucoMON and the Automated Diabetes Management System addressed the work of getting glucose information from daily life into timely family and care-team awareness. Instead of relying entirely on handwritten logs or delayed downloads, the architecture connected a glucose meter to wireless transmission and a hosted information service. Kevin led product architecture, development, commercialization, and deployment into research and care programs.
The operating architecture
The work covered device interfaces, collection of readings, wireless transmission, remote device management, hosted data handling, automated rules, reporting, and notifications. GlucoDYNAMIX supported the backend analysis and feedback environment. Kevin’s patent application describes a wider architecture connecting patients, devices, servers, and management teams.
The system design considered both individual events and longitudinal patterns. It supported delivery of information to caregivers through practical communication channels, with an emphasis on reducing additional participant effort. The specific configuration varied across device generations and programs.
Clinical research use
The 2012 Diabetes Care randomized controlled technology trial evaluated the Automated Diabetes Management System in families of children with type 1 diabetes. Forty-eight children were followed for 12 months. The system automatically collected glucose values and provided parents with recurring trend information. The published study reported better glycemic outcomes in the intervention group, with use frequency relevant to the observed improvement.
Kevin McMahon is a co-author. This evidence supports the particular intervention and population studied. It does not establish that all connected devices or every later program produced the same result.
Public technical record
US20050038680A1 names Kevin McMahon as inventor and records priority in December 2002, filing in February 2004, and publication in February 2005. The application covers remote monitoring, data movement, analysis, communications, and patient-management workflows. It is identified here as a patent application, not an active granted patent.
Contemporary D CEO and David Mendosa reporting provide additional historical accounts of the technology. These sources are useful because they describe the product while it was being introduced, rather than relying only on a later retrospective.
Transferable engineering and product judgment
Kevin’s contribution spans the physical product, the network, the hosted software, the data model, and the human workflow. That combination is relevant to modern connected medical products and sensor-based clinical systems, where a measurement has value only when it arrives reliably and is interpreted in context.
The experience also supplies a foundation for evaluating emerging technology without assuming that connectivity alone creates a useful care intervention. The product must fit the user’s routine and the responsibilities of the people receiving the information.
Sources and record basis
- Peer-reviewed researchDiabetes Care · 2012 randomized controlled trial
A 12-month study of 48 children evaluated automated glucose-data collection and family feedback. Kevin McMahon is a co-author. The findings concern the intervention studied; they are not a claim about every later product.
- Publication identifierDiabetes Care · DOI 10.2337/dc11-1597
Persistent identifier for the randomized controlled technology trial.
- Patent applicationGoogle Patents · US20050038680A1
Names Kevin McMahon as inventor. Priority: December 19, 2002; filing: February 3, 2004; publication: February 17, 2005. The publication documents an architecture; it is not presented as an active granted patent.
- Independent reportingD CEO · Help for Diabetics, 2007
Contemporary reporting on Diabetech, wireless glucose data, rules, and patient-to-caregiver connectivity.
- Independent reportingDavid Mendosa · GlucoMON
Historical reporting on automated glucose transmission and family/caregiver notifications. Original-site access may vary.
GlucoMON transmitted glucose-meter readings. Its record does not establish CGM sensor development or use of Dexcom in the ADMS trial. US20050038680A1 is a historical patent application naming Kevin as inventor. The archive does not establish an active granted patent.